The addition of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), to chemotherapy has been shown to increase the efficacy of therapy in metastatic colorectal cancer [27]. Here, VEGFA is linked to metastatic colorectal cancer.